Molecular prognostic markers in malignant mesothelioma

Priya Kumar, Robert A Kratzke

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Malignant mesothelioma remains a highly lethal cancer. Recent advances in both surgical and medical therapy have improved survival, but the treatments remain toxic and selection of appropriate patients for these therapies is difficult. Research into the molecular pathways involved in the development of mesothelioma should yield information that will guide therapeutic decisions in the near future. In particular, expression of EGFR and VEGF receptor hold promise to alter standards of patient care in the next few years. Alterations in cell cycle control proteins such as p16, p21, and p27 also offer information on prognosis and represent potential targets for therapy.

Original languageEnglish (US)
Pages (from-to)S53-S60
JournalLung Cancer
Issue numberSUPPL. 1
StatePublished - Jul 1 2005


  • Malignant mesothelioma
  • Prognostic markers
  • Tumor

Fingerprint Dive into the research topics of 'Molecular prognostic markers in malignant mesothelioma'. Together they form a unique fingerprint.

Cite this